We therefore investigated the associations between breast cancer risk and these TP53 and MDM2 polymorphisms in a large series of BRCA1 and BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (Chenevix-Trench et al, 2007). This evidence concerns the gene TP53 and breast carcinoma.